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of the EUCLIDS consortiumAbstract
Background: Sepsis is one of the main reasons for non-elective admission to pediatric intensive care units (PICUs),
but little is known about determinants influencing outcome. We characterized children admitted with community-
acquired sepsis to European PICUs and studied risk factors for mortality and disability.
Methods: Data were collected within the collaborative Seventh Framework Programme (FP7)-funded EUCLIDS study,
which is a prospective multicenter cohort study aiming to evaluate genetic determinants of susceptibility and/or severity
in sepsis. This report includes 795 children admitted with community-acquired sepsis to 52 PICUs from seven European
countries between July 2012 and January 2016. The primary outcome measure was in-hospital death.
Secondary outcome measures were PICU-free days censured at day 28, hospital length of stay, and disability.
Independent predictors were identified by multivariate regression analysis.
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Results: Patients most commonly presented clinically with sepsis without a source (n = 278, 35%), meningitis/
encephalitis (n = 182, 23%), or pneumonia (n = 149, 19%). Of 428 (54%) patients with confirmed bacterial infection,
Neisseria meningitidis (n = 131, 31%) and Streptococcus pneumoniae (n = 78, 18%) were the main pathogens. Mortality
was 6% (51/795), increasing to 10% in the presence of septic shock (45/466). Of the survivors, 31% were discharged
with disability, including 24% of previously healthy children who survived with disability. Mortality and disability were
independently associated with S. pneumoniae infections (mortality OR 4.1, 95% CI 1.1–16.0, P = 0.04; disability OR 5.4,
95% CI 1.8–15.8, P < 0.01) and illness severity as measured by Pediatric Index of Mortality (PIM2) score (mortality OR 2.8,
95% CI 1.3–6.1, P < 0.01; disability OR 3.4, 95% CI 1.8–6.4, P < 0.001).
Conclusions: Despite widespread immunization campaigns, invasive bacterial disease remains responsible for
substantial morbidity and mortality in critically ill children in high-income countries. Almost one third of sepsis
survivors admitted to the PICU were discharged with some disability. More research is required to delineate the
long-term outcome of pediatric sepsis and to identify interventional targets. Our findings emphasize the importance of
improved early sepsis-recognition programs to address the high burden of disease.
Keywords: Bacteremia, Meningococcal infections, Pneumococcal infections, Mortality, MorbidityBackground
Pediatric sepsis represents one of the most common rea-
sons for pediatric intensive care unit (PICU) admission,
and the prevalence and mortality in high-income coun-
tries has become comparable to that in adults [1–5]. In
2013, 10% of childhood deaths under the age of 5 years
in high-income countries were attributable to infections,
with the majority of acute infection-related deaths oc-
curring in PICUs [6]. Recent reports have demonstrated
the major impact of comorbidities with increasing rates
of healthcare-associated infections [1, 2, 4, 5, 7–9].
In contrast, recent data on community-acquired sepsis
are limited. Community-acquired sepsis represents spe-
cific patterns, affecting different hosts, and involving dif-
ferent pathogens, which may translate into different
outcomes compared to healthcare-associated infections
[10, 11]. In view of the need to develop improved strat-
egies for early recognition and treatment of sepsis, as
demanded by the recent resolution of the World Health
Organization [12], it is imperative to assess contempor-
ary characteristics of epidemiology and severity predic-
tors for community-acquired sepsis [13]. Previous larger
epidemiological sepsis studies have been predominantly
based on hospital coding or PICU databases with mor-
tality as the main outcome [1, 5]. A recent roadmap for
future sepsis research highlighted the inherent limita-
tions of such approaches, identifying the need to define
the longer-term impact on survivors [14]. While increas-
ing evidence in neonatal and adult patients demonstrates
that new cognitive impairment, functional disability, and
impaired quality of life are common amongst sepsis sur-
vivors [15–18], little is known about disability in
pediatric sepsis survivors [19, 20].
The aim of this study was to characterize the clinical
presentation, pathogens, mortality, and disability in chil-
dren admitted to European PICUs with community-acquired sepsis, based on patients recruited through the
multinational prospective European Childhood Life-
threatening Infectious Disease Study (EUCLIDS).
Methods
Consortium and study sites
The EUCLIDS is a Seventh Framework Programme (FP7)
project in the context of the European Union’s Research
and Innovation funding program for 2007–2013. This
large-scale prospective, multicenter, cohort study aimed to
identify genes, and biological pathways that determine
susceptibility and severity in life-threatening bacterial in-
fections of childhood. The EUCLIDS clinical network
includes predominantly academic pediatric hospitals that
host a total of 52 PICUs from 7 European countries;
Austria (9), Germany (7), Lithuania (1), The Netherlands
(5), Spain (9), Switzerland (8), and the UK (13).
Study patients
From July 2012 to January 2016, patients aged 29 days
to 18 years admitted with community-acquired sepsis to
PICUs in participating centers were prospectively
enrolled in the study. The 2005 pediatric consensus cri-
teria for sepsis were used, dividing patients into those
with sepsis, severe sepsis, or septic shock [21].
Healthcare-associated infections [22], patients undergo-
ing bone marrow transplant, and patients already re-
cruited who were readmitted within the same illness
episode were excluded. Children with a central venous
catheter at admission were not excluded. Although the
consortium was specifically interested in patients with
invasive meningococcal, pneumococcal, staphylococcal,
salmonella, and group A streptococcal infections, repre-
senting the most common causes of community-
acquired sepsis in children, patients with illness due to
other organisms were included as well. Patients were
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window from presentation to the time when culture re-
sults became available.
Ethical aspects
This study was conducted in accordance with the Declar-
ation of Helsinki and Good Clinical Practice guidelines.
The study protocol was approved by at least one ethical
review board in every country (Coordinating Center Re-
search Ethics Committee reference: 11/LO/1982) [23].
Written informed consent was obtained from parents or
legal guardians. In the Swiss study [24, 25], consent was
obtained for collection of blood for research, but waiver of
consent for collection of anonymized epidemiological data
was approved.
Clinical data collection
Data on clinical presentation, underlying disease, illness
severity, management, microbiological results, and out-
come were collected prospectively. Children were split
into four age categories; infants (29 days to < 1 year), tod-
dlers (≥ 1 year to < 5 years), school-aged children (≥ 5 years
to < 12 years), and adolescents (≥ 12 years to < 18 years).
Underlying conditions at admission to the PICU were
classified following the pediatric complex chronic condi-
tions classification system [26]. Illness severity was mea-
sured by the Pediatric risk of mortality score (PRISM) [27]
and Pediatric Index of Mortality (PIM2) [28]. We studied
lactate values obtained on admission, concomitant with
PIM2 data collection. Invasive bacterial infections were
defined as isolation by culture or PCR of a bacterial organ-
ism from a normally sterile site. We considered blood,
cerebrospinal fluid, urine, bronchoalveolar lavage, joint as-
pirate, abscess aspirate, intraoperative swabs, and pleural
aspirate as sterile sites. Urine positive for pneumococcal
antigen was also considered as an invasive bacterial infec-
tion if patients met sepsis criteria. Positive cultures from
sites such as endotracheal tube aspirate, nasopharyngeal
aspirate, throat/nasal swabs, and wounds were not consid-
ered as sterile sites. We defined potentially vaccine-
preventable infections as infections caused by pathogens
that are included in currently available national
immunization programs, with a focus on Haemophilus
influenzae type B (HiB), meningococcus serogroups
ACWY (MenACWY), meningococcus serogroup B
(MenB), meningococcus serogroup C (MenC), pneumo-
coccal conjugate vaccine 7 (PCV7, Prevnar, serotypes 4,
6B, 9V, 14, 18C, 19F and 23F), pneumococcal conjugate
vaccine 10 (PCV10, Synflorix, additional serotypes 1, 5,
7F), pneumococcal conjugate vaccine 13 (PCV13, Prevnar
13, additional serotypes 3, 6A, 19A) and pneumococcal
polysaccharide vaccine 23 (PPSV23, additional serotypes
2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, 33F). Data on
routine immunization schedules and uptake in thecountries involved are presented in Additional file 1:
Table S1. We classified patients as primary blood-
stream infection and sepsis without a known source
(grouped as no focus) versus patients with a clinical
focus of infection. Patients admitted with systemic in-
flammatory response syndrome (SIRS) in the presence
of suspected infection (i.e. sepsis), in whom a bacter-
ial, viral, or fungal infection eventually could not be
confirmed, were categorized as clinical presentation
other.
Outcomes
The primary outcome measure was death in hospital,
recorded as alive or death status at the time of hospital
discharge. Secondary outcomes were assessed at time of
hospital discharge and included disability, PICU-free
days censored at day 28 (days alive and free from the
need for intensive care), and hospital length of stay. Dis-
ability was defined as a Pediatric Overall Performance
Category (POPC) scale > 1 [29], need for skin graft,
amputation, or hearing loss. The POPC scale was deter-
mined either by direct observation or by chart review
and ranges from 1 to 6: (1) good overall performance,
(2) mild overall disability, (3) moderate overall disability,
(4) severe overall disability, (5) coma or vegetative state,
and (6) brain death. A description of these categories
is presented in Additional file 1: Table S2 [29]. PICU-
free days in patients who died were considered zero.
All data were collected in web-based case report
forms. Monthly telephone conferences, biannual meet-
ings, clinical protocols including case definitions, data
audits, and monitoring, ensured uniform procedures
among study sites.
Statistical analysis
Categorical variables are presented as counts (percent-
ages). We used the chi-Square test or Fisher’s exact
test to compare frequency distributions between two
categorical variables. Post-hoc Bonferroni correction
for multiple testing was applied when we compared
age groups with features on clinical presentation or
pathogens. Continuous variables are presented either
as mean (± standard deviation (SD)) for data with a
parametric distribution or as median (interquartile
range (IQR)) for non-parametric data. We tested dif-
ferences between groups with analysis of variance
(ANOVA) or Kruskal-Wallis and Student’s t test, or
Mann-Whitney U test, as appropriate. Logistic regres-
sion (of binary outcome measures) and linear regres-
sion (of continuous outcome measures) were used to
identify independent predictors. Variables with a P
value <0.20 in the univariable analysis were included
in the multivariable analysis. In the multivariable ana-
lysis, we only included one parameter of illness
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ness severity parameters. Area under the receiver op-
erating characteristic (AUROC) curve analysis was
applied to determine the Youden index. Sensitivity,
specificity, positive predictive value (PPV), negative
predictive value (NPV), positive likelihood ratio (PLR)
, and negative likelihood ratio (NLR) were calculated
for the optimal cutoff value of lactate. Statistical ana-
lyses were performed with SPSS version 21 (Armonk,
USA). Graphs were created in GraphPad Prism 5.00.
A P value <0.05 was considered statistically
significant.
Results
From July 2012 to January 2016, 795 children (54%
male, median age 2.2 years (IQR 8 months to 6 years))
admitted with community-acquired sepsis to 52 PICUs
in 7 European countries were enrolled (Fig. 1). Baseline
characteristics by age category are presented in Table 1.
An underlying condition was present in 288 patients
(36%), of which prematurity and neonatal conditions
(n = 87, 11%) and neurologic and neuromuscular condi-
tions were most common (n = 70, 9%). A total of 466
patients (59%) presented with septic shock.
Clinical presentations and pathogens
Primary bloodstream infection and sepsis without a known
source among patients with community-acquired sepsis
accounted for 278 (35%) admissions to the PICU. The otherFig. 1 Patients admitted with community-acquired sepsis to European pediatric
Infectious Disease Studymost common clinical illnesses were meningitis/encephal-
itis (n = 182, 23%) and pneumonia (n = 149, 19%)
(Additional file 1: Figure S1). Clinical presentation were
similar across age groups, apart from osteomyelitis/septic
arthritis, which was diagnosed more frequently in school-
aged children than in infants (7.3% versus 0.4%, P value =
0.002).
Bacterial etiology was confirmed in 428 patients
(54%), including 334 patients (42%) with a positive
blood culture, and pathogen distribution was associ-
ated with age (Fig. 2). Neisseria meningitidis was the
most commonly identified pathogen (n = 131, 31%), of
which serogroup B was most prevalent (n = 89, 68%),
followed by Streptococcus pneumoniae (n = 78, 18%, of
which serotypes 3 (n = 7, 14%) and 10A (n = 6, 12%)
were most commonly identified in those with serotyp-
ing information available (n = 51)) (Additional file 1:
Table S3).
Of the 466 patients with septic shock, an invasive
bacterial infection was confirmed in 255 patients
(55%). N. meningitidis (n = 91, 36%) and group A
streptococcus (n = 49, 19%) were the most commonly
identified pathogens, followed by Streptococcus pneu-
moniae (n = 33, 13%).
Therapy
Invasive ventilation was used in 519 patients (69%)
(median length of invasive respiratory support 5 days,
IQR 3–8, n = 43 with missing data) and vasoactiveintensive care units (PICUs). EUCLIDS, European Childhood Life-threatening
Table 1 Baseline characteristics of children admitted with community-acquired sepsis to PICU
All patients
(n = 795)
29 days–12 months
(n = 261)
1–5 years
(n = 278)
5–12 years
(n = 151)
12–18 years
(n = 105)
P
Sex (male n, %) 428 (54%) 151 (58%) 148 (53%) 76 (50%) 53 (51%) ns
Age 2 years
(8 months–6 years)
5 months
(2–8 months)
2 years
(18 months–3 years)
8 years
(6–10 years)
15 years
(14–16 years)
–
Ethnicitya ns
African/North African 46 (6%) 15 (6%) 12 (4%) 14 (10%) 5 (5%)
Asian 57 (7%) 22 (9%) 18 (7%) 10 (7%) 7 (7%)
European 607 (79%) 195 (76%) 222 (82%) 106 (75%) 84 (82%)
Meso/South American 7 (1%) 1 (0%) 3 (1%) 1 (1%) 2 (2%)
Middle Eastern 10 (1%) 5 (2%) 1 (0%) 2 (1%) 2 (2%)
Other/mixed 45 (6%) 18 (7%) 15 (6%) 9 (6%) 3 (3%)
Time interval onset symptoms to hospital
admissionb (days)
1 (1–3) 1 (0–3) 2 (1–) 2 (0–4) 1 (1–3) ns
Immunizations up to datec 585 (89%) 177 (82%) 219 (89%) 114 (95%) 75 (97%) < 0.001
Number of underlying conditions < 0.01
None 507 (64%) 176 (67%) 192 (69%) 85 (56%) 54 (51%)
1 175 (22%) 55 (21%) 53 (19%) 36 (24%) 31 (30%)
≥ 2 113 (14%) 30 (12%) 33 (12%) 30 (20%) 20 (19%)
Underlying conditions < 0.01
Neurologic and neuromuscular 70 (9%) 6 (2%) 17 (6%) 27 (18%) 20 (19%)
Cardiovascular 52 (7%) 14 (5%) 27 (10%) 8 (5%) 3 (3%)
Respiratory 40 (5%) 14 (5%) 12 (4%) 9 (6%) 5 (5%)
Renal and urologic 18 (2%) 5 (2%) 8 (3%) 2 (1%) 3 (3%)
Gastrointestinal 35 (4%) 9 (3%) 11 (4%) 8 (5%) 7 (7%)
Hematologic or immunologic 11 (1%) 2 (0%) 4 (1%) 4 (3%) 1 (1%)
Metabolic 20 (3%) 5 (2%) 6 (2%) 5 (3%) 4 (4%)
Other congenital or genetic defect 56 (7%) 9 (3%) 18 (6%) 17 (11%) 12 (11%)
Malignancy 9 (1%) 1 (0%) 1 (0%) 2 (1%) 5 (5%)
Premature and neonatal 87 (11%) 56 (21%) 19 (7%) 9 (6%) 3 (3%)
Other 52 (7%) 10 (4%) 16 (6%) 14 (9%) 12 (11%)
Illness severity
PRISM scored 14 (7–21) 14 (7–22) 15 (8–22) 14 (8–21) 11 (4–16) < 0.01
PIM2 scoree (predicted death, %) 4.0 (1.1–9.5) 4.0 (1.0–8.2) 4.8 (1.1–10.3) 4.2 (1.1–
17.1)
3.3 (0.9–9.0) ns
Lactate at PICU admissionf (mmol/L) 1.8 (1.1–3.4) 1.6 (1.0–3.2) 1.6 (1.0–3.2) 2.2 (1.1–3.7) 2.3 (1.2–4.7) ns
Septic shock (n, %) 466 (59%) 133 (51%) 168 (60%) 94 (62%) 71 (68%) < 0.05
Values are reported as counts (percentages) or medians (interquartile ranges), unless stated otherwise
Abbreviations: PICU pediatric ICU, PRISM Pediatric Risk of Mortality [27], PIM2 Pediatric Index of Mortality 2 [28], ns not significant
aEthnicity data were available for 772/795 patients; 256/261 infants, 271/278 toddlers, 142/151 school-aged children, and 103/105 adolescents
bTime interval from onset of symptoms to hospital admission was available for 642/795 patients; 212/261 infants, 229/278 toddlers, 111/151 school-aged children,
and 90/105 adolescents
cImmunization data were available for 657/795 patients; 215/261 infants, 245/278 toddlers, 120/151 school-aged children, and 77/105 adolescents
dPRISM score was available for 672/795 patients; 223/261 infants, 240/278 toddlers, 118/151 school-aged children, and 91/105 adolescents
ePIM2 score was available for 681/795 patients; 224/261 infants, 243/278 toddlers, 123/151 school-aged children, and 91/105 adolescents
fLactate at PICU admission was available for 444/795 patients; 146/261 infants, 167/278 toddlers, 76/151 school-aged children, and 55/105 adolescents
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5 days, n = 56 with missing data). Infants needed inva-
sive ventilation more frequently than adolescents
(73% versus 58%, P value = 0.03).Mortality and PICU-free survival
Of the 795 children admitted to PICU with community-
acquired sepsis, 51 patients (6%) died. Mortality
increased to 10% (n = 45) in patients with septic shock.
Fig. 2 Invasive pathogens in patients with community-acquired sepsis admitted to the pediatric intensive care unit. Invasive pathogens (n = 428)
by age category. Numbers are higher as three patients had mixed bacterial infections (one patient with Staphylococcus aureus/gram-negative bacteria, two
patients with gram-negative/gram-positive bacteria). The y-axis represents the percentage of respective pathogen within the age category, i.e. percentages
of all pathogens within an age category add up to 100%. d, days; m, months
Boeddha et al. Critical Care  (2018) 22:143 Page 6 of 13Univariable analysis showed that the presence of
bacteremia (odds ratio (OR) 4.4, 95% confidence interval
(CI) 2.3–8.4, P < 0.001) and infections caused by S. pneu-
moniae (OR 2.5, 95% CI 1.2–5.1, P = 0.01) were associ-
ated with mortality in patients with sepsis (Table 2). In
addition, illness severity, as measured by PRISM score,
PIM2 score, invasive ventilation, the need for inotropes,
and higher lactate at PICU admission, were also associ-
ated with sepsis mortality. The AUROC for lactate as a
predictor of mortality was 0.723 (95% CI 0.624–0.822),
with an optimal cutoff value of 2.2 mmol/L (sensitivity
0.78, specificity 0.60) (Additional file 1: Figure S2).
Infection caused by S. pneumoniae (OR 4.1, 95% CI 1.1–
16.0, P = 0.04) and illness severity (PIM2 score OR 2.8,95% CI 1.3–6.1, P < 0.01) remained independently signifi-
cantly associated with mortality in multivariable analysis.
A trend towards higher mortality was observed for
bacteremia (OR 7.4, 95% CI 1.0–56.6, P = 0.06). PICU
mortality did not differ significantly across age categories
or countries. Also, the presence of an underlying condi-
tion at admission to the PICU was not associated with
mortality.
The median PICU-free days to day 28 were 23 days
(IQR 18–25) and the median hospital length of stay was
12 days (IQR 8–21). PIM2 score (B = − 0.202, P < 0.001),
invasive S. pneumoniae infections (B = − 0.161, P = 0.02),
and invasive Staphylococcus aureus infections (B = − 0.163,
P = 0.01) were independent predictors of PICU-free days.
Table 2 Predictors of death in children with community-acquired sepsis
Sepsis survivors
(n = 744)
Deaths
(n = 51)
Univariable odds ratio
for death (95% CI)
P Multivariable odds ratio
for death (95% CI)
P
Sex
Male 399/744 (54%) 29/51 (57%) Reference
Female 345/744 (46%) 22/51 (43%) 0.9 (0.5–1.6) 0.65 NA
Age
29 days–12 months (infants) 248/744 (33%) 13/51 (26%) Reference
1–5 years (toddlers) 259/744 (35%) 19/51 (37%) 1.4 (0.7–2.9) 0.37 NA
5–12 years (school -aged children) 140/744 (19%) 11/51 (22%) 1.5 (0.7–3.4) 0.34 NA
12–18 years (adolescents) 97/744 (13%) 8/51 (16%) 1.6 (0.6–3.9) 0.33 NA
Time interval from onset of symptoms
to hospital admissiona (days)
1 (1–3) 2 (1–4) 1.0 (1.0–1.1) 0.47 NA
Immunizations up to date
No 70/621 (11%) 2/36 (6%) Reference
Yes 551/621 (89%) 34/36 (94%) 2.2 (0.5–9.2) 0.30 NA
Underlying condition
No 479/744 (64%) 28/51 (55%) Reference
Yes 265/744 (36%) 23/51 (45%) 1.5 (0.8–2.6) 0.18 0.7 (0.2–2.0) 0.46
Illness severity
PRISM scoreb 14 (7–20) 22 (15–30) 1.1 (1.0–1.1) < 0.001 NA
PIM2 scorec (predicted death, %) 3.9 (1.0–9.1) 14.7 (3.8–48.0) 3.9 (2.1–7.2) < 0.001 2.8 (1.3–6.1) < 0.01
Lactate at PICU admissiond (mmol/L) 1.7 (1.0–3.3) 3.3 (2.3–5.4) 8.9 (2.7–29.1) < 0.001 NA
Invasive ventilation 474/705 (67%) 45/47 (96%) 11.0 (2.6–45.6) 0.001 NA
Inotropes 377/693 (54%) 41/46 (89%) 6.9 (2.7–17.6) < 0.001 NA
Bacteremia
No 445/741 (60%) 13/51 (26%) Reference
Yes 296/741 (40%) 38/51 (75%) 4.4 (2.3–8.4) < 0.001 7.4 (1.0–56.6) 0.06
Clinical syndromes
No focus 254/744 (34%) 24/51 (47%) 1.7 (1.0–3.0) 0.06 3.0 (0.8–10.9) 0.09
Meningitis/encephalitis 172/744 (23%) 10/51 (20%) 0.8 (0.4–1.6) 0.56 NA
Pneumonia 138/744 (19%) 11/51 (22%) 1.2 (0.6–2.4) 0.59 NA
Other focus 180/744 (24%) 6/51 (12%) 0.4 (0.2–1.0) 0.05 1.8 (0.3–11.8) 0.52
Invasive pathogense
N. meningitidis 120/386 (31%) 11/39 (28%) 0.8 (0.4–1.8) 0.88 NA
S. pneumoniae 65/386 (17%) 13/39 (33%) 2.5 (1.2–5.1) 0.01 4.1 (1.1–16.0) 0.04
Group A streptococcus 60/386 (16%) 6/39 (15%) 1.0 (0.4–2.5) 1.0 NA
S. aureus 37/386 (10%) 4/39 (10%) 1.1 (0.4–3.2) 0.88 NA
Other invasive pathogen 104/386 (27%) 5/39 (13%) 0.4 (0.2–1.0) 0.06 0.3 (0.0–2.2) 0.21
This study included 795 children admitted with community-acquired sepsis, of whom 51 patients died. Multivariable analysis included variables with a P value
< 0.20 in univariable analysis. Because parameters of illness severity are strongly correlated, only the Pediatric Index of Mortality 2 (PIM2) [28] score has been
included in multivariable analysis. Values are reported as counts (percentages) or medians (interquartile ranges), unless stated otherwise
PRISM Pediatric Risk of Mortality [27], NA not applicable
aTime interval from onset of symptoms to hospital admission was available for 609/744 sepsis survivors and 33/51 non-survivors
bPRISM score was available for 636/744 sepsis survivors and 36/51 non-survivors
cPIM2 score was available for 645/744 sepsis survivors and 36/51 non-survivors. Data were log transformed for univariable and multivariable analysis
dData on lactate at pediatric ICU admission were available for 421/744 sepsis survivors and 23/51 non-survivors. Data were log transformed for univariable analysis
eBacterial etiology was confirmed in 428 patients, including 3 patients with mixed invasive pathogens in culture results: these 3 patients have been excluded,
leaving 425 patients for analysis
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Boeddha et al. Critical Care  (2018) 22:143 Page 8 of 13PIM2 score (B = 0.270, P < 0.001), pneumonia (B = 0.145,
P = 0.04), and invasive Staphylococcus aureus infections
(B = 0.234, P = 0.001) were independent predictors of
hospital length of stay (Additional file 1: Table S4).
Disability
Data on disability at discharge were available on 558/744
survivors (75%). Of these patients, 173/558 (31%) were
discharged with disability including 71 patients (13%)
with mild overall disability, 39 (7%) with moderate
overall disability, 50 (9%) with severe overall disability, 4
(0.7%) who had undergone amputation, 2 (0.4%) with
hearing loss, and 7 (1.3%) who had undergone skin graft.
Toddlers (34%) and school-aged children (42%) were
more often discharged with disability than infants (21%,
P value <0.05).
Among survivors who did not have an underlying
condition at admission to PICU, i.e. previously
healthy children, 24% (83/349 patients whose data
were available) were discharged with some disability.
Disability data were available on 339/421 (81%) survi-
vors of septic shock. In these, 120/339 (35%) patients
had disability at PICU discharge, including 45 (13%)
with mild overall disability, 29 (9%) with moderate
overall disability, 35 (10%) with severe overall disabil-
ity, 4 (1.2%) who had undergone amputation, and 7
(2.0%) who had undergone skin graft. Outcome as
measured by mortality and POPC score was worst in
patients admitted with pneumonia (Additional file 1:
Figure S3) and in patients with invasive bacterial in-
fections caused by Streptococcus pneumoniae (Add-
itional file 1: Figure S4). When comparing patients
discharged with and without disability, by univariable
and multivariable analysis, the PIM2 score (OR 3.4,
95% CI 1.8–6.4, P < 0.001) and infections caused by
Streptococcus pneumoniae (OR 5.4, 95% CI 1.8–15.8,
P < 0.01) were independent predictors of disability
(Table 3).
Economic impact of vaccine-preventable infections
Assuming an average cost per PICU day of 4000 €
and 1000 € per day on a general ward, we estimate
an average cost of 42,000 € per vaccine-preventable
episode of severe community-acquired infection re-
quiring admission to a PICU. This calculation was
based on the mean hospital length of stay (18 days),
including mean PICU length of stay (8 days), of the
subgroup of patients with vaccine-preventable infec-
tions (n = 149). Within our consortium, a total of 149
vaccine-preventable cases reflect 43 cases per year.
The impact on cost and resource utilization for the
hospitals included was estimated at almost 2 million
€ for potentially vaccine-preventable infections
annually.Discussion
This prospective multicenter study of 795 children
admitted with community-acquired sepsis to European
PICUs demonstrates the substantial burden of severe
invasive bacterial disease, despite widespread immunization
programs, predominantly affecting previously healthy chil-
dren [30]. Almost one third of survivors (31%) were dis-
charged with disability ranging from mild to severe.
We observed a crude mortality rate of 6% in children
admitted with sepsis. Other studies have reported higher
mortality of up to 29% in high-income countries, which
may relate to the large number of hospital-acquired infec-
tions with a disproportionate impact of high-risk patients
such as those with oncologic conditions or those undergo-
ing transplant in other cohorts [1, 2, 4, 5, 8, 31–33]. The
enrolment criteria in our study were based on the 2005
consensus pediatric sepsis definition, and we included
patients with sepsis in addition to patients with severe
sepsis and septic shock, which may account for the lower
mortality observed. However, most study patients were
admitted to the PICU because of single or multiple organ
dysfunction, and hence would be expected to meet the
Sepsis-3-based sepsis definitions too [21, 34]. The limita-
tions of current pediatric sepsis definitions including the
low predictive accuracy of SIRS [35], and the need to
adapt Sepsis-3 for pediatric age groups, have been
highlighted recently [36].
We observed that 1 out of 3 sepsis survivors were dis-
charged with a disability, including 1 in 10 with severe
disability and/or amputation. Notably, 24% of previously
healthy children left the hospital with some form of dis-
ability. While there is a lack of large studies on pediatric
sepsis long-term outcomes, similar incidence of disabil-
ity has been reported in two other studies, with a decline
in functional status observed in 28 to 34% of pediatric
sepsis survivors [4, 20]. Others have observed impaired
neuropsychological performance and impaired educa-
tional functioning [19]. Our findings highlight the need
to include disability as an outcome measure in pediatric
sepsis trials in the future. More research is required to
delineate the nature of the disabilities and to study the
add-on effect of sepsis when underlying conditions are
already present. Disability in children with underlying
conditions could be evaluated more accurately in the fu-
ture by reporting changes in performance scales between
admission and discharge.
Independent risk factors for death, disability, and
PICU-free days were illness severity - reflected by sever-
ity scores - and invasive pneumococcal infections. Our
findings indicate that while current PICU severity scores
were calibrated against mortality, PIM performs very
well to predict disability as well, which indicates that
some patients predicted to die survive, yet with a major
impact on functional status. Larger studies are urgently
Table 3 Predictors of disability in survivors of community-acquired sepsis
No disability at discharge
(n = 385)
Disability at discharge
(n = 173)
Univariable odds ratio
for disability (95% CI)
P Multivariable odds ratio
for disability (95% CI)
P
Sex
Male 196/385 (51%) 90/173 (52%) Reference
Female 189/385 (49%) 83/173 (48%) 1.0 (0.7–1.4) 0.81 NA
Age
29 days–12 months (infants) 145/385 (38%) 38/173 (22%) Reference
1–5 years (toddlers) 135/385 (35%) 70/173 (41%) 2.0 (1.3–3.1) < 0.01 1.8 (0.8–4.1) 0.14
5–12 years
(school-aged children)
55/385 (14%) 39/173 (23%) 2.7 (1.6–4.7) < 0.001 2.6 (1.0–7.0) 0.05
12–18 years (adolescents) 50/385 (13%) 26/173 (15%) 2.0 (1.1–3.6) 0.02 2.0 (0.7–6.0) 0.20
Time interval from onset of
symptoms to hospital admissiona
(days)
1 (1–3) 1 (1–3) 1.0 (0.9–1.0) 0.16 0.9 (0.9–1.0) 0.07
Immunizations up to date
No 29/334 (9%) 17/157 (11%) Reference
Yes 305/334 (91%) 140/157 (89%) 0.8 (0.4–1.5) 0.45 NA
Underlying condition
No 266/385 (69%) 83/173 (48%) Reference
Yes 119/385 (31%) 90/173 (52%) 2.4 (1.7–3.5) < 0.001 1.9 (0.9–3.6) 0.08
Illness severity
PRISM score 12 (6–19) 16 (11–23) 1.1 (1.0–1.1) < 0.001 NA
PIM2 scoreb
(predicted death, %)
3.1 (0.9–7.1) 6.8 (2.3–17.2) 2.7 (1.9–3.9) < 0.001 3.4 (1.8–6.4) < 0.001
Lactate at PICU admissionc
(mmol/L)
1.6 (1.0–3.2) 2.3 (1.2–4.5) 2.0 (1.0–3.8) 0.04 NA
Invasive ventilation 242/370 (65%) 139/167 (83%) 2.6 (1.7–4.2) < 0.001 NA
Inotropes 196/365 (54%) 112/166 (68%) 1.8 (1.2–2.6) < 0.01 NA
Bacteremia
No 262/385 (68%) 112/173 (65%) Reference
Yes 123/385 (32%) 61/173 (35%) 1.2 (0.8–1.7) 0.44 NA
Clinical syndromes
No focus 146/385 (38%) 48/173 (28%) 0.6 (0.4–0.9) 0.02 0.9 (0.3–2.4) 0.83
Meningitis/encephalitis 74/385 (19%) 49/173 (28%) 1.7 (1.1–2.5) 0.02 1.0 (0.3–3.2) 0.95
Pneumonia 57/385 (15%) 49/173 (28%) 2.3 (1.5–3.5) < 0.001 1.2 (0.4–3.8) 0.73
Other focus 108/385 (28%) 27/173 (16%) 0.5 (0.3–0.8) < 0.01 1.0 (0.3–3.0) 0.96
Invasive pathogens
N. meningitidis 81/177 (45%) 18/87 (21%) 0.3 (0.2–0.6) < 0.001 0.5 (0.2–1.3) 0.16
S. pneumoniae 12/177 (7%) 27/87 (31%) 6.3 (3.0–13.2) < 0.001 5.4 (1.8–15.8) < 0.01
Group A streptococcus 31/177 (18%) 15/87 (17%) 1.0 (0.5–2.0) 1.0 NA
S. aureus 16/177 (9%) 11/87 (13%) 1.5 (0.7–3.4) 0.34 NA
Other invasive pathogen 37/177 (21%) 16/87 (18%) 0.9 (0.4–1.6) 0.63 NA
This study included 795 children with community-acquired sepsis, of whom 173 patients were discharged with disability, i.e. Pediatric Overall Performance
Category score 2– 5 [29], need of skin graft, hearing loss, or need of amputation (51 deaths and 186 patients with missing data are not included in this
analysis). Multivariable analysis included variables with a P value < 0.20 in univariable analysis. Because parameters of illness severity are strongly correlated,
only the Pediatric Index of Mortality 2 (PIM2) score [28] has been included in multivariable analysis. Values are reported as counts (percentages) or medians
(interquartile ranges), unless stated otherwise
PRISM Pediatric Risk of Mortality [27], NA not applicable
aTime interval from onset of symptoms to hospital admission was available for 372/385 patients without disability and for 154/173 patients with
disability at discharge
bData were log transformed for univariable and multivariable analysis
cData on lactate at pediatric ICU admission were available for 247/385 patients without disability and for 109/173 patients with disability at discharge.
Data were log transformed for univariable analysis
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Boeddha et al. Critical Care  (2018) 22:143 Page 10 of 13needed to assess long-term impact, as this patient group
is at high risk of prolonged dependency on health sup-
port, reduced school and work life performance, and re-
duced quality of life, resulting in an under recognized
disproportionate impact of sepsis on our society [14].
Lactate was associated with mortality and the optimal
cutoff value of 2.2 mmol/L in serum supports using
lactate as a trigger threshold in National Institute for
Health and Care Excellence (NICE) UK guidelines [37].
Previous studies have demonstrated the strong associ-
ation between lactate and mortality, and indicated that
both arterial and venous serum lactate level can be used
for risk stratification [38–41]. Importantly, our study
demonstrated that increased lactate levels at PICU ad-
mission were associated with disability too.
An invasive bacterial infection was confirmed in half of
the children, which is comparable to pathogen detection
rates from 30 to 65% in other studies [1, 4, 5, 33]. The
most common community-acquired invasive pathogens in
our study were meningococci - especially serogroup B
(menB) - and pneumococci - especially serotypes 3 and
10A. Recently, a menB vaccine (Bexsero®) has been li-
censed for active immunization against menB and this
vaccine has been implemented in the Czech Republic and
UK routine immunization schedules [42, 43]. It had been
anticipated that this vaccine would cover approximately
70 to 80% of MenB strains, depending on geographical re-
gion and age [30, 42]. Preliminary data report 93% vaccine
uptake of two doses by 12 months of age [44]. Future
studies should determine the impact on disease and herd
protection. Meningococcal serogroup C immunization re-
sulted in a significant drop in incidence of over 80% in the
UK and over 90% in The Netherlands [45–47]. In con-
trast, invasive MenW disease is increasing and careful
monitoring in the coming years is necessary [48].
Immunization against pneumococcal disease is recom-
mended in almost all European countries, and has been
proven effective in the decline of invasive pneumococcal
infections [49]. In the post-immunization era, the inci-
dence of non-vaccine serotypes has however increased,
suggesting serotype replacement [49]. Additionally, vac-
cine failure does occur. Primary immunodeficiency is
present in up to 26% of children > 2 years of age with
invasive pneumococcal infections after introduction of
vaccination, indicating that infected patients should
undergo immunological investigations [50]. Pneumo-
coccal serotype 3 is included in Prevnar 13 (PCV13),
but not in Synflorix (PCV10). Limited vaccine effect-
iveness for serotype 3 has been reported previously
[51, 52]. Pathogen detection is complicated by early
administration of antibiotics and by low circulating
microbial loads [53]. Therefore, new diagnostics to
improve pathogen detection and optimal antimicrobial
therapy are urgently needed [54].Despite widespread vaccination campaigns in Europe
effectively targeting invasive pneumococcal disease [43,
55–57], the burden due to these potentially vaccine-
preventable infections has remained considerable: 17 %
of patients with pneumococcal infections have died,
while 35% of the patients have been discharged with
some form of disability. The pneumococcal mortality
rate in our study is slightly higher than mortality rates
from other PICU studies [2, 8, 58]. However, those
studies relied on ICD-9 codes for organisms and did
not evaluate specific culture results. Therefore, a num-
ber of infections might have been classified based on
non-sterile site cultures (e.g. nasopharyngeal aspirate),
and thus could have identified a colonized location,
whereas we confirmed each invasive pneumococcal in-
fection by sterile site positive detection. On the other
hand, our definition of invasive pneumococcal infection
might have skewed the results away from respiratory
infections, towards central nervous system infections,
as we considered blood, pleural aspirate, and broncho-
alveolar lavage as invasive detection sites for pneumo-
nia. These sites are not routinely screened in patients
with pneumonia. Nevertheless, our findings emphasize
the importance and the need to continuously improve
current immunization programs. Additionally, reducing
potentially vaccine-preventable infections will have a
beneficial effect on economic resources. We estimated
an average cost of 42,000 € per vaccine preventable epi-
sode of severe community-acquired infection requiring
PICU. In comparison, a recent Australian and New
Zealand study [5] estimated the mean cost per ICU and
ward admission for sepsis and septic shock of
AUS$62062 (equal to 39,000 €). Beside direct costs in
severe cases requiring PICU admission, the total eco-
nomic impact of vaccine-preventable diseases encom-
passes direct costs in cases not requiring PICU
admission, and indirect costs related to loss of revenue
of caregivers and long-term costs related to permanent
disability.
This study has several limitations, most of them relat-
ing to the design of this large, international consortium.
First, the primary aim of our consortium was to identify
genes associated with susceptibility and severity of inva-
sive meningococcal, pneumococcal, staphylococcal, and
group A streptococcal infections, which might have
caused an enrollment bias in favor of infections caused
by these organisms. Therefore, data on the prevalence
and distribution of pathogens need to be interpreted
with caution. Second, due to the genetic basis of this
study, a bias towards enrollment of previously healthy
children might have occurred. In our cohort, only 36%
of patients had an underlying condition at admission,
whereas in other studies percentages varying from 49 to
77% are reported, yet these studies included hospital-
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assessed disability by the easily applicable and well-
validated pediatric overall performance scale at discharge
[29, 59]. However, there is a fair amount of disability
data missing, possibly because of loss to follow up after
patients had been transferred back to the local hospital
prior to discharge. For patients with disability data avail-
able, we did not take further recovery after discharge
into account. Fourth, the EUCLIDS consortium repre-
sents a network of institutions active in infectious dis-
eases research and was not designed to provide
population-based coverage. Hence we are unable to
compare findings between countries and we are unable
to estimate the impact of vaccine-preventable disease on
mortality, morbidity, and costs at population level.
Finally, our consortium includes multiple centers from
multiple countries, representing a different epidemio-
logical context, healthcare structures, and case-mix.
Nevertheless, this study includes the largest prospect-
ively enrolled contemporary cohort of children with
community-acquired sepsis in high-income countries.
Because previous pediatric sepsis studies included
healthcare-associated infections, results from this study
especially have implications for policy makers in public
health, e.g. to develop immunization strategies. Last, this
report differs from previous reports because we included
disability as an outcome measure, thereby meeting the
need to improve our understanding of the short-term
physical effects of sepsis and understanding the implica-
tions for sepsis survivors [14].
Conclusions
This report from high-income countries describes a large
cohort of children admitted with community-acquired
sepsis to European PICUs, providing contemporary assess-
ment of the epidemiology and characteristics of one of the
most common reasons for PICU admission. Our study
demonstrates the substantial burden caused by community-
acquired sepsis, predominantly affecting previously
healthy children. One out of three survivors was
discharged with disability, indicating an urgent need
for improved recognition, treatment, and follow up of
children with sepsis.
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